Reviewer's report

Title: Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin when Co-administered in Subjects with Type 2 Diabetes Mellitus

Version: 4 Date: 25 January 2013

Reviewer: David Boulton

Reviewer's report:

The manuscript is acceptable.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I am an employee/shareholder of Bristol-Myers Squibb Co., which has a compound in development that is also an SGLT2 inhibitor.